Mingyi Chen

Mingyi Chen is a Professor in the Department of Pathology at the University of Texas Southwestern Medical Center. His academic background includes a Medical Degree from Peking University Health Science Center (1992), postgraduate training in Pharmacology at Kyoto University (2001), and a postdoctoral fellowship at UCLA/Howard Hughes Medical Institute (2005). He has expertise in Hematopathology, with a focus on tumor suppression mechanisms, molecular oncology, and the integration of artificial intelligence in diagnostic pathology.

His research explores the bone marrow microenvironment's role in multiple myeloma drug resistance, TP73 isoform functions in tumor suppression, and ferredoxin-driven lipid metabolism pathways. Notable contributions include advancements in AI-driven flow cytometry and digital pathology for hematologic malignancy diagnosis.

Publications emphasize AI applications in diagnostics, molecular evaluation of myeloproliferative disorders, and therapeutic resistance mechanisms. He has authored over 111 papers, with recent work on Ferredoxin proteins' roles in tumor suppression and CAR-T therapy-associated hepatic lymphoma. His work bridges basic science and clinical translation, addressing challenges in hematologic malignancies and therapeutic innovation.